Ose immuno press release
WebOct 7, 2024 · OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer, effective immediately.... WebFeb 22, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF …
Ose immuno press release
Did you know?
WebFeb 15, 2024 · Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) ... This … WebOther than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the …
WebFeb 15, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2024, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics’ website. WebMar 11, 2024 · Immuno-oncology platform. BI 765063 (OSE-172, anti-SIRPα mAb on SIRPα/CD47 pathway): ... This press release includes only summary information and …
WebFeb 15, 2024 · OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating tumor... WebOct 7, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF …
WebJul 13, 2024 · NANTES, France, July 13, 2024 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings an impressive track record of successes in Pharma across a range of …
WebFeb 15, 2024 · OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the company has signed a loan agreement of up to €25 million with the … oh where art thou romeoWebJun 23, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF … oh what wow he\u0027s the greatest dancerWebJun 6, 2024 · Oslo, Norway, 6 June 2024: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid ... myinfo8WebThis press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 28 April 2024 under the … oh when the weatherman comesWebSep 8, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF … myinfo accessWebJun 23, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF … myinfo 8.0WebSep 22, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF … oh where can my baby be